DDInter596 DDInter1863
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452]
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Triclabendazole
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Triclabendazole
Doxorubicin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Triclabendazole
Doxorubicin {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is downregulated by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Triclabendazole
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Fostemsavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Doxorubicin {u} (Compound) causes {v} (Side Effect) Purpura
Purpura {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Triclabendazole
Doxorubicin {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is downregulated by {v} (Compound) Bisacodyl
Bisacodyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Doxorubicin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Doxorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Doxorubicin (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Doxorubicin (Compound) causes Purpura (Side Effect) and Purpura (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Doxorubicin (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Doxorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole